HIV-1 envelope protein vaccine induces more robust antibody responses in infants than adults
Broadly neutralizing antibodies (bnAbs) develop more robustly in infants living with HIV-1 than adults, suggesting that vaccine-induced bnAbs may be more readily generated in infants. We evaluated a recombinant HIV-1 CH505TF gp120 monomer adjuvanted with GLA-SE in infants without HIV-1, born to mothers living with HIV-1, in a phase 1 randomized, placebo-controlled trial (HVTN135). Two weeks post-fifth dose, all vaccinated infants developed vaccine-specific CH505-positive B cells, IgG CH505TF gp120-specific binding antibodies (bAbs), and vaccine-matched Tier 1A neutralizing antibodies (nAbs); 86% had CD4 binding-site- (CD4bs) specific IgG + B cells and 43% had CD4bs-directed bAbs based on reduced binding to a CD4bs mutant (Δ371I). Compared to healthy adults from a harmonized phase 1 trial (HVTN115), infant IgG bAb titers and Tier 1A nAb ID50 titers were higher. Maternal antibody interference was not detected. Infant bAbs to routine immunizations were unaffected. These data support that infants can respond to a candidate adjuvanted HIV-1 vaccine with a greater magnitude of HIV-specific humoral responses than adults.
Authors
- Sheetal S. Sawant (ORCID: https://orcid.org/0000-0002-1109-7907)
- Kelly E. Seaton (ORCID: https://orcid.org/0000-0002-2009-3270)
- David C. Montefiori (ORCID: https://orcid.org/0000-0003-0856-6319)
- Genevieve G. Fouda (ORCID: https://orcid.org/0000-0002-0960-1019)
- Avy Violari (ORCID: https://orcid.org/0000-0002-9437-776X)
- K. Rachael Parks (ORCID: https://orcid.org/0000-0002-5307-4455)
- Kinga K. Smolen (ORCID: https://orcid.org/0000-0001-8650-3693)
- Nonhlanhla N. Mkhize (ORCID: https://orcid.org/0000-0003-3037-1243)
- Georgia D. Tomaras (ORCID: https://orcid.org/0000-0001-8076-1931)
- Laura Polakowski (ORCID: https://orcid.org/0000-0002-5476-7632)
- James J. Kobie (ORCID: https://orcid.org/0000-0001-8069-0272)
- Guido Ferrari (ORCID: https://orcid.org/0000-0001-7747-3349)
- Holly Janes (ORCID: https://orcid.org/0000-0002-3237-984X)
- Troy M. Martin (ORCID: https://orcid.org/0009-0004-7535-5436)
- Barton F. Haynes (ORCID: https://orcid.org/0000-0002-7643-9023)
- Kennedy N. Otwombe (ORCID: https://orcid.org/0000-0002-7433-4383)
- Kevin J. Wiehe (ORCID: https://orcid.org/0000-0001-9933-9618)
- Lawrence Corey (ORCID: https://orcid.org/0000-0002-2179-2436)
- Ofer Levy (ORCID: https://orcid.org/0000-0002-5859-1945)
- Jack Heptinstall (ORCID: https://orcid.org/0000-0002-3401-5935)
- Margaret Brewinski Isaacs
- Prudence Kgagudi
- Haajira Kaldine (ORCID: https://orcid.org/0000-0002-7946-5606)
- Robert Parks (ORCID: https://orcid.org/0000-0002-6259-7610)
- Wilton B. Williams (ORCID: https://orcid.org/0000-0002-2970-7259)
- Magdalena E. Sobieszczyk (ORCID: https://orcid.org/0000-0002-7112-3118)
- Penny L. Moore (ORCID: https://orcid.org/0000-0001-8719-4028)
- Madison Berry (ORCID: https://orcid.org/0009-0003-0332-3817)
- Glenda Gray (ORCID: https://orcid.org/0000-0003-4649-1477)
- Lu Zhang
- Yue Chen
- Shiyu Chen
- Amanda S Woodward Davis
- William O. Hahn
- Paul T Edelfsen
- Mathew Clark
Institutions
- Boston Children's Hospital (US)
- Duke University (US)
- University of the Witwatersrand (ZA)
- Cornell University (US)
- University of Alabama at Birmingham (US)
- Fred Hutch Cancer Center (US)
- Duke Medical Center (US)
- National Institute of Allergy and Infectious Diseases (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-19
- DOI
- https://doi.org/10.21203/rs.3.rs-11626851/v1
- Primary Topic
- HIV Research and Treatment
- Type
- preprint